Clinical Trials Logo

Cardiomegaly clinical trials

View clinical trials related to Cardiomegaly.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05953831 Withdrawn - Clinical trials for Heart Failure With Preserved Ejection Fraction

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

REMOD-REVERT
Start date: April 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess efficacy and safety of CDR132L on reverse remodeling. In this study, patients with HFpEF (EF ≥50%) or HFmrEF (LVEF 45-49%) will be included.

NCT ID: NCT01556568 Withdrawn - Cardiomegaly Clinical Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether the ability of MEK162 to antagonize MEK activation in NS HCM patients, who usually have upstream mutations in the Ras-Raf-Mek-Erk pathway that lead to MEK activation, would be beneficial over a 6 month treatment period in hypertrophy regression.